GlassScriptPhysician profile
Upasana Chohan
NPI 1013303148
$1,912.11
in general payments reported to CMS, 2019-2025
31 companies · $13.85 in 2025
The $13.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $131 · 2021: $215 · 2022: $561 · 2023: $466 · 2024: $241 · 2025: $13.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $285.80 | 2021-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $207.44 | 2019-2024 | Afrezza |
| Corcept Therapeutics | $141.24 | 2021-2023 | Korlym |
| Amgen INC. | $126.85 | 2019-2024 | Otezla, Enbrel |
| Ucb, INC. | $87.00 | 2023-2024 | Rystiggo, Zilbrysq |
| Lilly USA, LLC | $85.70 | 2022-2024 | Mounjaro, Jardiance |
| Teva Pharmaceuticals USA, INC. | $84.80 | 2021-2023 | Austedo |
| Pfizer INC. | $79.39 | 2019-2022 | |
| Dexcom, INC. | $70.08 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $66.03 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $61.12 | 2019-2020 | |
| Abbvie INC. | $59.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $58.98 | 2023-2024 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $50.28 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $47.56 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46.78 | 2019 | |
| Xeris Pharmaceuticals, INC. | $45.21 | 2022-2023 | Gvoke Hypopen |
| Shire North American Group INC | $41.69 | 2019 | |
| Lundbeck LLC | $39.48 | 2022 | |
| Amneal Pharmaceuticals LLC | $36.34 | 2019 | |
| Gilead Sciences, INC. | $29.43 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.28 | 2023 | |
| Avion Pharmaceuticals | $19.46 | 2023 | Balcoltra |
| Horizon Therapeutics Plc | $19.18 | 2020 | |
| Upsher-Smith Laboratories LLC | $17.72 | 2023 | |
| Dynavax Technologies Corporation | $15.38 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.08 | 2021 | |
| Acadia Pharmaceuticals INC | $14.08 | 2024 | Nuplazid |
| Exact Sciences Corporation | $13.96 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.79 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upasana Chohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.